ALT
Price
$5.17
Change
+$0.20 (+4.02%)
Updated
Apr 24 closing price
Capitalization
398.16M
13 days until earnings call
DNLI
Price
$15.47
Change
+$0.60 (+4.03%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
2.25B
18 days until earnings call
Ad is loading...

ALT vs DNLI

Header iconALT vs DNLI Comparison
Open Charts ALT vs DNLIBanner chart's image
Altimmune
Price$5.17
Change+$0.20 (+4.02%)
Volume$1.47M
Capitalization398.16M
Denali Therapeutics
Price$15.47
Change+$0.60 (+4.03%)
Volume$33.51K
Capitalization2.25B
ALT vs DNLI Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. DNLI commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and DNLI is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ALT: $5.17 vs. DNLI: $15.49)
Brand notoriety: ALT and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 54% vs. DNLI: 94%
Market capitalization -- ALT: $398.16M vs. DNLI: $2.25B
ALT [@Biotechnology] is valued at $398.16M. DNLI’s [@Biotechnology] market capitalization is $2.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 3 bearish.
  • DNLI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALT is a better buy in the short-term than DNLI.

Price Growth

ALT (@Biotechnology) experienced а +13.63% price change this week, while DNLI (@Biotechnology) price change was +21.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ALT is expected to report earnings on Aug 07, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.25B) has a higher market cap than ALT($398M). DNLI (-27.036) and ALT (-28.294) have similar YTD gains . ALT has higher annual earnings (EBITDA): -94.81M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. ALT (132M). ALT has less debt than DNLI: ALT (1.68M) vs DNLI (48.7M). ALT has higher revenues than DNLI: ALT (20K) vs DNLI (0).
ALTDNLIALT / DNLI
Capitalization398M2.25B18%
EBITDA-94.81M-492.89M19%
Gain YTD-28.294-27.036105%
P/E RatioN/AN/A-
Revenue20K0-
Total Cash132M832M16%
Total Debt1.68M48.7M3%
FUNDAMENTALS RATINGS
ALT vs DNLI: Fundamental Ratings
ALT
DNLI
OUTLOOK RATING
1..100
1015
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
9439
PRICE GROWTH RATING
1..100
8664
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (94) in the Biotechnology industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.

ALT's Profit vs Risk Rating (90) in the Miscellaneous Commercial Services industry is in the same range as DNLI (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for ALT (94) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew somewhat faster than ALT’s over the last 12 months.

DNLI's Price Growth Rating (64) in the Biotechnology industry is in the same range as ALT (86) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIAGX19.94N/A
N/A
Fidelity Advisor International Growth A
IRGTX9.91N/A
N/A
VY® CBRE Global Real Estate S
KTCSX34.74N/A
N/A
DWS Science and Technology S
RYDKX86.53N/A
N/A
Rydex Dow Jones Industrial Average® C
ANVHX8.97N/A
N/A
American Century Non-US Intrs Val I

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.85%
BEAM - DNLI
59%
Loosely correlated
+3.87%
RCKT - DNLI
57%
Loosely correlated
+2.44%
NTLA - DNLI
56%
Loosely correlated
-2.65%
ARWR - DNLI
56%
Loosely correlated
+5.26%
RGNX - DNLI
56%
Loosely correlated
+13.43%
More